Oral Panax notoginseng Preparation for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials

Table 2

Analysis of cardiovascular events and angina pectoris.

Outcomes (comparisons)	Treatment group (n/N)	Control group (n/N)	RR	95% CI
(1) Cardiovascular mortality
Panax notoginseng preparation and conventional therapy versus conventional therapy
Yu 2010 [31]	1/50	2/50	0.50	[0.05, 5.34]
(2) Myocardial infarction incidence
Panax notoginseng preparation and conventional therapy versus conventional therapy
Wang et al. 2009 [28]	0/100	3/100	0.14	[0.01, 2.73]
Yu 2010 [31]	0/50	2/50	0.20	[0.01, 4.06]
	Overall all (FEM, 𝐼^2=0%)		0.17	[0.02, 1.37]
(3) Incidence of intractable angina pectoris
Panax notoginseng preparation and conventional therapy versus conventional therapy
Wang et al. 2009 [28]	6/100	11/100	0.55	[0.21, 1.42]
(4) Rehospitalization incidence for unstable angina
Panax notoginseng preparation and conventional therapy versus conventional therapy
Han and Chen 2008 [23]	1/30	3/30	0.33	[0.04, 3.03]
(5) Recurrence of angina pectoris
Panax notoginseng preparation and conventional therapy versus conventional therapy
Han and Chen 2008 [23]	5/30	13/30	0.38	[0.16, 0.94]
(6) Nitroglycerol decreasement
Panax notoginseng preparation and conventional therapy versus conventional therapy
Ji and Zhang 2003 [24]	19/30	65/120	1.17	[0.85, 1.61]
Song et al. 2005 [26]	26/50	14/50	1.86	[1.11, 3.12]
	Overall all (REM, 𝐼^2=59%)		1.41	[0.89, 2.24]
(7) Angina pectoris relievement
Panax notoginseng preparation and conventional therapy versus conventional therapy
Ge and Zhao 2010 [22]	44/48	36/48	1.22	[1.02, 1.47]
Ji and Zhang 2003 [24]	24/30	77/120	1.25	[1.00, 1.56]
Wan 2011 [27]	24/26	19/26	1.26	[0.98, 1.64]
Wei 2010 [29]	84/90	75/90	1.12	[1.01, 1.25]
Yu 2010 [31]	48/50	43/50	1.12	[0.98, 1.27]
Zhou and Bai 2009 [32]	37/43	30/43	1.23	[0.98, 1.55]
Bao 2011 [34]	57/63	45/64	1.29	[1.08, 1.54]
	Overall all (FEM, 𝐼^2=0%, 𝑁=791)		1.20	[1.12, 1.28]
Subgroup analysis (excluded Ji and Zhang [24])	Overall (FEM, 𝐼^2=0%, 𝑁=641)		1.19	[1.11, 1.27]
(8) Electrocardiogram improvement
15.1 Panax notoginseng preparation and conventional therapy versus conventional therapy
Ge and Zhao 2010 [22]	42/48	36/48	1.17	[0.96, 1.42]
Ji and Zhang 2003 [24]	67/86	19/29	1.19	[0.89, 1.58]
Liu et al. 2008 [19]	12/30	8/30	1.50	[0.72, 3.14]
Song et al. 2005 [26]	36/50	27/50	1.33	[0.98, 1.82]
Wan 2011 [27]	19/26	12/26	1.58	[0.98, 2.55]
Yu 2010 [31]	28/50	19/50	1.47	[0.96, 2.27]
Zhou and Bai 2009 [32]	35/43	27/43	1.30	[0.99, 1.70]
Zhao and Li 2012 [35]	24/60	12/58	1.93	[1.07, 3.49]
	Overall all (FEM, 𝐼^2=0%, 𝑁=727)		1.35	[1.19, 1.53]
Subgroup analysis (excluded Ji and Zhang [24])	Overall (FEM, 𝐼^2=0%, 𝑁=612)		1.39	[1.21, 1.59]
15.2 Panax notoginseng preparation and conventional therapy versus isosorbide dinitrate and conventional therapy
Meng 2003 [25]	19/60	8/20	0.79	[0.41, 1.52]
(9) Angina pectoris immediate effect
Panax notoginseng preparation and conventional therapy versus isosorbide dinitrate and conventional therapy
Meng 2003 [25]	52/60	18/20	0.96	[0.81, 1.15]

FEM: fixed effects model; REM: random effects model; RR: relative risk; CI: credibility interval.